Overview Performance Dividends Peer Group Options

(BEAT) Heartbeam - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US42238H1086

BEAT: Electrocardiogram, Diagnostic Software, Cardiac Monitoring Systems

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company specializing in the development and commercialization of advanced ambulatory electrocardiogram (ECG) solutions. The companys technology enables the detection and monitoring of cardiac diseases both in clinical settings and remotely. HeartBeams innovative approach involves creating three-dimensional vector images of cardiac electrical activity, providing a more comprehensive view of heart function compared to traditional ECG methods.

The companys flagship product, HeartBeam AIMIGo, is a credit card-sized, cloud-based diagnostic system designed for the early detection of heart attacks. This portable solution aims to improve patient outcomes by enabling timely and accurate diagnosis outside of traditional healthcare facilities. HeartBeam Inc. was founded in 2015 and is headquartered in Santa Clara, California, a hub for medical technology innovation. For more information, visit their website at https://www.heartbeam.com.

HeartBeam operates in the Health Care Equipment sector, with a focus on developing cutting-edge solutions for cardiac care. The companys ticker symbol is BEAT, listed on the NASDAQ exchange as a common stock. Its market capitalization is approximately $68.13 million USD, with a price-to-book ratio of 13.70, indicating strong investor confidence in its growth potential.

Ticker Symbol: BEAT Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Health Care Equipment Average Volume 20d: 101,961 Last Price: 2.11 SMA 20: 2.16 SMA 50: 2.20 SMA 200: 2.41 ATR: 0.16 Market Cap: 68.13M USD P/E: 0.00 P/E Forward: 0.00 P/B: 13.70 P/S: 0.00 RoE: None 3-Month Forecast Based on the provided and , HeartBeam Inc. (BEAT) is expected to trade within a narrow range over the next three months. The stocks price action is likely to remain bounded by the SMA 50 ($2.20) and SMA 200 ($2.41), with potential support near the SMA 20 ($2.16). The low ATR (0.16) suggests limited volatility, but the lack of earnings and revenue growth could weigh on investor sentiment. From a perspective, the companys high P/B ratio (13.70) reflects investor optimism about its long-term prospects, particularly the commercialization of HeartBeam AIMIGo. However, the absence of positive P/E and P/S metrics highlights the speculative nature of the investment. Overall, the stock may experience modest upward movement if the company announces progress in its product pipeline or regulatory approvals, but downside risks remain due to its developmental stage and lack of profitability.

Additional Sources for BEAT Stock

News: Wall Street Journal Benzinga Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

BEAT Stock Overview

Market Cap in USD 68m
Sector Healthcare
Industry Health Information Services
GiC Sub-Industry Health Care Equipment
IPO / Inception 2021-11-11

BEAT Stock Ratings

Growth 5y -32.9%
Fundamental -13.1%
Dividend 0.0%
Rel. Strength Industry -11.6
Analysts 4/5
Fair Price Momentum 1.81 USD
Fair Price DCF -

BEAT Dividends

No Dividends Paid

BEAT Growth Ratios

Growth Correlation 3m -69.9%
Growth Correlation 12m 2.1%
Growth Correlation 5y 1.8%
CAGR 5y -22.35%
CAGR/Max DD 5y -0.28
Sharpe Ratio 12m -1.43
Alpha -18.93
Beta 0.73
Volatility 75.88%
Current Volume 27.1k
Average Volume 20d 76.9k
What is the price of BEAT stocks?
As of March 14, 2025, the stock is trading at USD 2.02 with a total of 27,072 shares traded.
Over the past week, the price has changed by -4.72%, over one month by -7.34%, over three months by -35.26% and over the past year by -11.79%.
Is Heartbeam a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Heartbeam is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -13.11 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BEAT as of March 2025 is 1.81. This means that BEAT is currently overvalued and has a potential downside of -10.4%.
Is BEAT a buy, sell or hold?
Heartbeam has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy BEAT.
  • Strong Buy: 1
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecast for BEAT stock price target?
According to ValueRays Forecast Model, BEAT Heartbeam will be worth about 2 in March 2026. The stock is currently trading at 2.02. This means that the stock has a potential downside of -0.5%.
Issuer Forecast Upside
Wallstreet Target Price 5 147.5%
Analysts Target Price 5 147.5%
ValueRay Target Price 2 -0.5%